Although several steps downstream of a possible SHARPIN deficit-initiated pathology, initial studies with an anti-IL-33 monoclonal antibody (etokimab) showed promising results for reduction in skin inflammation associated with AD ([74]; reviewed in [75]). This evidence concerns the gene SHARPIN and Alzheimer disease.